First publication from NEURO-TTRansform trial in the treatment of patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)

Consistent and sustained benefit on all co-primary and secondary endpoints across patients with a diverse range of disease characteristics